2023 Q1 Form 10-K Financial Statement
#000155837023002907 Filed on March 06, 2023
Income Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
Revenue | $47.60M | $11.03M | $27.15M |
YoY Change | 1231.5% | 678.26% | 341.5% |
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $18.69M | $15.22M | $61.09M |
YoY Change | 11.25% | 2.99% | 6.61% |
% of Gross Profit | |||
Research & Development | $25.55M | $23.05M | $127.7M |
YoY Change | -30.49% | -21.87% | 14.98% |
% of Gross Profit | |||
Depreciation & Amortization | $1.659M | $1.437M | $5.266M |
YoY Change | 19.7% | -35.68% | -6.47% |
% of Gross Profit | |||
Operating Expenses | $25.55M | $38.27M | $127.7M |
YoY Change | -30.49% | -13.57% | 14.98% |
Operating Profit | $1.656M | -$164.0M | |
YoY Change | -103.31% | 1.06% | |
Interest Expense | $676.0K | $523.0K | $1.542M |
YoY Change | 100.0% | 192.18% | 40.05% |
% of Operating Profit | 40.82% | ||
Other Income/Expense, Net | -$671.0K | -$1.537M | -$536.0K |
YoY Change | -5691.67% | -138.08% | -113.91% |
Pretax Income | $1.661M | -$28.26M | -$163.0M |
YoY Change | -103.35% | -26.89% | 3.6% |
Income Tax | $625.0K | $994.0K | $2.497M |
% Of Pretax Income | 37.63% | ||
Net Earnings | $1.036M | -$29.25M | -$165.5M |
YoY Change | -102.06% | -24.73% | 4.66% |
Net Earnings / Revenue | 2.18% | -265.23% | -609.46% |
Basic Earnings Per Share | $0.00 | -$0.17 | |
Diluted Earnings Per Share | $0.00 | -$0.03 | -$0.17 |
COMMON SHARES | |||
Basic Shares Outstanding | 991.8M | 983.0M | 967.2M |
Diluted Shares Outstanding | 1.000B | 967.2M |
Balance Sheet
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $165.6M | $204.6M | $204.6M |
YoY Change | -45.58% | -44.64% | -44.64% |
Cash & Equivalents | $119.9M | $108.0M | $108.0M |
Short-Term Investments | $45.69M | $96.57M | $96.57M |
Other Short-Term Assets | $1.664M | $1.927M | $12.68M |
YoY Change | -20.87% | -7.44% | 6.8% |
Inventory | |||
Prepaid Expenses | $6.787M | $9.472M | |
Receivables | $1.715M | $7.435M | $7.435M |
Other Receivables | $36.72M | $30.65M | $30.65M |
Total Short-Term Assets | $213.7M | $255.4M | $255.4M |
YoY Change | -40.54% | -38.53% | -38.53% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $54.37M | $53.52M | $71.54M |
YoY Change | 48.18% | 75.5% | 39.26% |
Goodwill | |||
YoY Change | |||
Intangibles | $443.0K | $442.0K | |
YoY Change | -43.78% | -55.8% | |
Long-Term Investments | |||
YoY Change | |||
Other Assets | $1.578M | $1.569M | $1.569M |
YoY Change | -8.04% | -8.67% | -8.67% |
Total Long-Term Assets | $74.33M | $73.55M | $73.55M |
YoY Change | 23.19% | 35.98% | 35.98% |
TOTAL ASSETS | |||
Total Short-Term Assets | $213.7M | $255.4M | $255.4M |
Total Long-Term Assets | $74.33M | $73.55M | $73.55M |
Total Assets | $288.1M | $328.9M | $328.9M |
YoY Change | -31.38% | -29.95% | -29.95% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $5.187M | $4.753M | $4.753M |
YoY Change | -26.08% | -41.42% | -41.42% |
Accrued Expenses | $33.21M | $31.22M | $31.79M |
YoY Change | 5.01% | 4.37% | -0.36% |
Deferred Revenue | $22.30M | $23.52M | |
YoY Change | -9.96% | 5.95% | |
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $63.63M | $64.50M | $64.50M |
YoY Change | -3.81% | 3.13% | 3.13% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $1.332M | $1.296M | $182.5M |
YoY Change | 98.81% | 92.57% | -9.21% |
Total Long-Term Liabilities | $1.332M | $1.296M | $182.5M |
YoY Change | 98.81% | 92.57% | -9.21% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $63.63M | $64.50M | $64.50M |
Total Long-Term Liabilities | $1.332M | $1.296M | $182.5M |
Total Liabilities | $204.2M | $247.0M | $247.0M |
YoY Change | -20.44% | -6.28% | -6.28% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$908.3M | -$909.3M | |
YoY Change | 14.38% | 22.24% | |
Common Stock | $1.407M | $1.399M | |
YoY Change | 4.84% | 4.64% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $83.88M | $81.88M | $81.88M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $288.1M | $328.9M | $328.9M |
YoY Change | -31.38% | -29.95% | -29.95% |
Cashflow Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | $1.036M | -$29.25M | -$165.5M |
YoY Change | -102.06% | -24.73% | 4.66% |
Depreciation, Depletion And Amortization | $1.659M | $1.437M | $5.266M |
YoY Change | 19.7% | -35.68% | -6.47% |
Cash From Operating Activities | -$37.28M | $2.042M | -$141.8M |
YoY Change | -31.47% | -98.48% | -1421.36% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $2.349M | $3.428M | $29.50M |
YoY Change | -66.98% | -184.81% | 244.02% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $50.86M | $24.38M | $118.9M |
YoY Change | 2074.56% | -199.72% | 40.55% |
Cash From Investing Activities | $48.34M | $20.95M | $89.14M |
YoY Change | -1112.38% | -173.54% | 17.59% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 196.0K | 1.403M | 12.87M |
YoY Change | 460.0% | 2598.08% | 291.33% |
NET CHANGE | |||
Cash From Operating Activities | -37.28M | 2.042M | -141.8M |
Cash From Investing Activities | 48.34M | 20.95M | 89.14M |
Cash From Financing Activities | 196.0K | 1.403M | 12.87M |
Net Change In Cash | 11.84M | 24.40M | -42.06M |
YoY Change | -119.6% | -76.87% | -146.64% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$37.28M | $2.042M | -$141.8M |
Capital Expenditures | $2.349M | $3.428M | $29.50M |
Free Cash Flow | -$39.63M | -$1.386M | -$171.3M |
YoY Change | -35.57% | -101.0% | -8047.33% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.17 | |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-130092000 | |
CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.15 | |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.17 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
967242403 | |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
934833017 | |
CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
854783763 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-165456000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-158090000 | |
CY2022 | us-gaap |
Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
|
0 | |
CY2021 | us-gaap |
Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
|
0 | |
CY2020 | us-gaap |
Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
|
0 | |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-130092000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
|
0 | |
CY2020 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
|
0 | |
CY2022 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
60421000 | |
CY2021 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
5808000 | |
CY2020 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-19220000 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
|
0 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-49581000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-6435000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-165456000 | |
CY2020 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
CY2022 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-573000 | |
CY2020 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
16364000 | |
CY2022 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
CY2021 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-461000 | |
CY2020 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
161000 | |
CY2021 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
|
0 | |
CY2020 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
89000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
|
0 | |
CY2020 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
|
0 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
|
6000 | |
CY2022 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-155189000 | |
CY2021 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-159184000 | |
CY2020 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
5663000 | |
CY2020 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-132876000 | |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
123638000 | |
CY2020 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-2784000 | |
CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
10414000 | |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-130092000 | |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
341227000 | |
CY2021 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
759000 | |
CY2021 | adap |
Stock Sold During Period Ordinary Shares Value
StockSoldDuringPeriodOrdinarySharesValue
|
2529000 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-1094000 | |
CY2021 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
20629000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-158090000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
205960000 | |
CY2022 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
50000 | |
CY2022 | adap |
Stock Sold During Period Ordinary Shares Value
StockSoldDuringPeriodOrdinarySharesValue
|
12817000 | |
CY2020 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.15 | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
967242403 | |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
934833017 | |
CY2020 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
854783763 | |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
987109890 | |
CY2021Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
||
CY2022Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
||
CY2022 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
00-0000000 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.17 | |
CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.17 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
10267000 | |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
18240000 | |
CY2022 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2022 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001621227 | |
CY2022 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | |
CY2022 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2022 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
X0 | |
CY2022 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
928547934 | |
CY2022 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2015Q3 | us-gaap |
Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
|
P15Y | |
CY2021 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off Statement Of Income Or Comprehensive Income Extensible Enumeration
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
|
http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense | |
CY2020 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off Statement Of Income Or Comprehensive Income Extensible Enumeration
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
|
http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense | |
CY2022 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off Statement Of Income Or Comprehensive Income Extensible Enumeration
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOffStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
|
http://fasb.org/us-gaap/2022#ResearchAndDevelopmentExpense | |
CY2022 | dei |
Document Type
DocumentType
|
10-K | |
CY2022 | dei |
Document Annual Report
DocumentAnnualReport
|
true | |
CY2022 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2022-12-31 | |
CY2022 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2022 | dei |
Entity File Number
EntityFileNumber
|
001-37368 | |
CY2022 | dei |
Entity Registrant Name
EntityRegistrantName
|
ADAPTIMMUNE THERAPEUTICS PLC | |
CY2022 | dei |
City Area Code
CityAreaCode
|
44 | |
CY2022 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
60 Jubilee Avenue, Milton Park | |
CY2022 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Abingdon, Oxfordshire | |
CY2022 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
OX14 4RX | |
CY2022 | dei |
Entity Address Country
EntityAddressCountry
|
GB | |
CY2022 | dei |
Local Phone Number
LocalPhoneNumber
|
1235 430000 | |
CY2022 | dei |
Security12b Title
Security12bTitle
|
American Depositary Shares, each representing | |
CY2022 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2022 | dei |
Trading Symbol
TradingSymbol
|
ADAP | |
CY2022 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2022 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2022 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2022 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2022 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2022 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2022 | dei |
Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
|
true | |
CY2022 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2022Q2 | dei |
Entity Public Float
EntityPublicFloat
|
244288811 | |
CY2023Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
991831158 | |
CY2022 | dei |
Auditor Firm
AuditorFirmId
|
1118 | |
CY2022 | dei |
Auditor Name
AuditorName
|
KPMG LLP | |
CY2022 | dei |
Auditor Location
AuditorLocation
|
Reading, United Kingdom | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
108033000 | |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
149948000 | |
CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
96572000 | |
CY2021Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
219632000 | |
CY2022Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
0 | |
CY2021Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
0 | |
CY2022Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
7435000 | |
CY2021Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
752000 | |
CY2022Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
43330000 | |
CY2021Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
45126000 | |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
255370000 | |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
415458000 | |
CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
1569000 | |
CY2021Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
1718000 | |
CY2022 | adap |
Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
|
9470000 | |
CY2021 | adap |
Operating Lease Right Of Use Asset Accumulated Amortization
OperatingLeaseRightOfUseAssetAccumulatedAmortization
|
7253000 | |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
18019000 | |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
20875000 | |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
38588000 | |
CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
36253000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
53516000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
30494000 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
4676000 | |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-129930000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
4051000 | |
CY2022Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
442000 | |
CY2021Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
1000000 | |
CY2022Q4 | us-gaap |
Assets
Assets
|
328916000 | |
CY2021Q4 | us-gaap |
Assets
Assets
|
469545000 | |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4753000 | |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
8113000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2728000 | |
CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2320000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
31215000 | |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
29909000 | |
CY2022Q4 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
2285000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
23520000 | |
CY2021Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
22199000 | |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
64501000 | |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
62541000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
20349000 | |
CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
23148000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
160892000 | |
CY2021Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
177223000 | |
CY2022Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1296000 | |
CY2021Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
673000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2497000 | |
CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
791000 | |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
247038000 | |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
263585000 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
162000 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1282773750 | |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
987109890 | |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1240853520 | |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
937547934 | |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1399000 | |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1337000 | |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
990656000 | |
CY2021Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
959611000 | |
CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-875000 | |
CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-11142000 | |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-909302000 | |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-743846000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
81878000 | |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
205960000 | |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
328916000 | |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
469545000 | |
CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
27148000 | |
CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
6149000 | |
CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
3958000 | |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
127726000 | |
CY2021 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
111090000 | |
CY2020 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
91568000 | |
CY2022 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
63387000 | |
CY2021 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
57305000 | |
CY2020 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
45795000 | |
CY2022 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
191113000 | |
CY2021 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
168395000 | |
CY2020 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
137363000 | |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-163965000 | |
CY2021 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-162246000 | |
CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-133405000 | |
CY2022 | us-gaap |
Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
|
1542000 | |
CY2021 | us-gaap |
Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
|
1095000 | |
CY2020 | us-gaap |
Interest Income Debt Securities Available For Sale Operating
InterestIncomeDebtSecuritiesAvailableForSaleOperating
|
2313000 | |
CY2022 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-536000 | |
CY2021 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
3852000 | |
CY2020 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
1162000 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-162959000 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-157299000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-165456000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-158090000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
81878000 | |
CY2022 | us-gaap |
Profit Loss
ProfitLoss
|
-165456000 | |
CY2021 | us-gaap |
Profit Loss
ProfitLoss
|
-158090000 | |
CY2020 | us-gaap |
Profit Loss
ProfitLoss
|
-130092000 | |
CY2022 | us-gaap |
Depreciation
Depreciation
|
5266000 | |
CY2021 | us-gaap |
Depreciation
Depreciation
|
5630000 | |
CY2020 | us-gaap |
Depreciation
Depreciation
|
6627000 | |
CY2022 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
809000 | |
CY2021 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
937000 | |
CY2020 | us-gaap |
Adjustment For Amortization
AdjustmentForAmortization
|
967000 | |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
18240000 | |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
20629000 | |
CY2020 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
10414000 | |
CY2022 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
2438000 | |
CY2021 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
-540000 | |
CY2020 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
1333000 | |
CY2022 | adap |
Amortization Accretion Of Marketable Securities
AmortizationAccretionOfMarketableSecurities
|
2525000 | |
CY2021 | adap |
Amortization Accretion Of Marketable Securities
AmortizationAccretionOfMarketableSecurities
|
5276000 | |
CY2020 | adap |
Amortization Accretion Of Marketable Securities
AmortizationAccretionOfMarketableSecurities
|
3836000 | |
CY2022 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
816000 | |
CY2021 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
1173000 | |
CY2020 | us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
-55000 | |
CY2022 | adap |
Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
|
9813000 | |
CY2021 | adap |
Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
|
19358000 | |
CY2020 | adap |
Increase Decrease In Current Assets
IncreaseDecreaseInCurrentAssets
|
-1747000 | |
CY2020 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-2458000 | |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
4408000 | |
CY2021 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
4207000 | |
CY2020 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
3867000 | |
CY2022 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
3874000 | |
CY2021 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
149785000 | |
CY2020 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
47973000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-141769000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
10729000 | |
CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-53591000 | |
CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
29496000 | |
CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
8574000 | |
CY2020 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2341000 | |
CY2022 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
244000 | |
CY2021 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
207000 | |
CY2020 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
565000 | |
CY2022 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
166994000 | |
CY2021 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
224343000 | |
CY2020 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
105022000 | |
CY2022 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
48117000 | |
CY2021 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
139762000 | |
CY2020 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
381040000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
89137000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
75800000 | |
CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-278924000 | |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
930000 | |
CY2022 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
12817000 | |
CY2021 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2529000 | |
CY2020 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
334388000 | |
CY2022 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
50000 | |
CY2021 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
759000 | |
CY2020 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
5663000 | |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
12867000 | |
CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3288000 | |
CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
340051000 | |
CY2022 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-2299000 | |
CY2021 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
365000 | |
CY2020 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-960000 | |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-42064000 | |
CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
90182000 | |
CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
6576000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
151666000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
61484000 | |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
54908000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
109602000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
151666000 | |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
61484000 | |
CY2022 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
5149000 | |
CY2021 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
7765000 | |
CY2020 | us-gaap |
Proceeds From Interest Received
ProceedsFromInterestReceived
|
6216000 | |
CY2022 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-2525000 | |
CY2021 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-5276000 | |
CY2020 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-3836000 | |
CY2022 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
630000 | |
CY2021 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
535000 | |
CY2020 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
75000 | |
CY2022 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Note 1</b><b style="font-weight:bold;"> </b><b style="font-weight:bold;">—</b><b style="font-weight:bold;"> General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Adaptimmune Therapeutics plc is registered in England and Wales. Its registered office is 60 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire, OX14 4RX, United Kingdom. Adaptimmune Therapeutics plc and its subsidiaries (collectively “Adaptimmune” or the “Company”) is a clinical-stage biopharmaceutical company primarily focused on providing novel cell therapies to people with cancer. The Company is </span>a leader in the development of T-cell therapies for solid tumors. The Company’s proprietary platform enables it to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage of clinical development including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical programs or clinical programs, the need to obtain marketing approval for its cell therapies, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of its cell therapies, the need to develop a reliable commercial manufacturing process, the need to commercialize any cell therapies that may be approved for marketing, and protection of proprietary technology. If the Company does not successfully commercialize any of its cell therapies<span style="white-space:pre-wrap;">, it will be unable to generate product revenue or achieve profitability. The Company had an accumulated deficit of </span>$909,302,000 as of December 31, 2022.</p> | |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-909302000 | |
CY2022 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(b)</b> <b style="font-weight:bold;">Use of estimates in financial statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements, in conformity with U.S. GAAP and SEC regulations, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and reported amounts of revenues and expenses during the reporting period. Estimates and assumptions are primarily made in relation to revenue recognition, estimation of the incremental borrowing rate for operating leases, and valuation allowances relating to deferred tax assets. If actual results differ from the Company’s estimates, or to the extent these estimates are adjusted in future periods, the Company’s results of operations could either benefit from, or be adversely affected by, any such change in estimate.</p> | |
CY2020 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
|
0 | |
CY2020 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
CY2020 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
|
0 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
|
0 | |
CY2021 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
CY2021 | us-gaap |
Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
|
0 | |
CY2022 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
|
0 | |
CY2022 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
|
0 | |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
|
19 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
108033000 | |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
149948000 | |
CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
1569000 | |
CY2021Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
1718000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
109602000 | |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
151666000 | |
CY2022 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
166994000 | |
CY2022 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
166994000 | |
CY2021 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
224343000 | |
CY2020 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
105022000 | |
CY2022 | us-gaap |
Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
|
0 | |
CY2021 | us-gaap |
Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
|
6000 | |
CY2020 | us-gaap |
Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
|
89000 | |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
90618000 | |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
176483000 | |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
|
36 | |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
390000 | |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
833000 | |
CY2022 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
CY2022 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
2316000 | |
CY2021 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
562000 | |
CY2020 | us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
889000 | |
CY2022 | adap |
Reimbursement Of Research And Development Tax And Expenditure Credit
ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit
|
30226000 | |
CY2021 | adap |
Reimbursement Of Research And Development Tax And Expenditure Credit
ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit
|
34082000 | |
CY2020 | adap |
Reimbursement Of Research And Development Tax And Expenditure Credit
ReimbursementOfResearchAndDevelopmentTaxAndExpenditureCredit
|
19442000 | |
CY2022 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
2810000 | |
CY2021 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
2505000 | |
CY2020 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
2070700 | |
CY2022 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-2525000 | |
CY2021 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-5276000 | |
CY2020 | us-gaap |
Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
|
-3836000 | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-165456000 | |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-158090000 | |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-130092000 | |
CY2022 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-165456000 | |
CY2021 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-158090000 | |
CY2020 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-130092000 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
967242403 | |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
934833017 | |
CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
854783763 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022 | us-gaap |
Costs Associated With Exit Or Disposal Activities Or Restructurings Policy Ongoing Benefit Arrangements
CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyOngoingBenefitArrangements
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(v)</b> <b style="font-weight:bold;">Restructuring costs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/><span style="white-space:pre-wrap;"> Restructuring costs are comprised of amounts payable to employees because of redundancy related to restructuring programs. The Company classifies redundancy payments as either, contractual termination benefits if they relate to an ongoing benefit arrangement, including terms of employment contracts or termination benefits that arise from employment law in the relevant jurisdiction, or, one-time employee termination benefits if the benefits are not related to an ongoing benefit arrangement or represent a one-time enhancement to an ongoing benefit arrangement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>A liability for contractual termination benefits is recognized when it is probable that employees will be entitled to benefits and the amount can be reasonably estimated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>A liability for one-time employee termination benefits is recognized from the communication date. If employees are not required to render service until they are terminated or will not be retained to render service beyond the minimum retention period in order to receive the termination benefits, a liability for one-time employee termination benefits is recognized at the communication date. If employees are required to render services beyond the minimum retention period in order to receive the termination benefits, a liability is measured initially at the communication date </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">based on the fair value of the liability as of the termination date and is recognized ratably over the required service period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"/>Restructuring costs are recognized within General and administrative expenses with the corresponding liability recognized in current or non-current liabilities depending on the expected timing of payments.</p> | |
CY2022 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
27148000 | |
CY2021 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
6149000 | |
CY2020 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
3958000 | |
CY2022Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
15010000 | |
CY2022Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
199422000 | |
CY2022Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
184412000 | |
CY2022 | adap |
Increase Decrease In Contract With Customer Change In Exchange Rate Liability
IncreaseDecreaseInContractWithCustomerChangeInExchangeRateLiability
|
20601000 | |
CY2021Q4 | us-gaap |
Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
|
1.35 | |
CY2022Q4 | us-gaap |
Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
|
1.21 | |
CY2022 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
17648000 | |
CY2021Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
147330000 | |
CY2021Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
52092000 | |
CY2021Q4 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
199422000 | |
CY2020 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
1498000 | |
CY2021Q3 | adap |
Collaboration Agreement Notice Period For Termination
CollaborationAgreementNoticePeriodForTermination
|
P180D | |
CY2021Q3 | adap |
Collaboration Agreement Number Of Days Without Hsr Clearance After Effective Date Before Termination
CollaborationAgreementNumberOfDaysWithoutHsrClearanceAfterEffectiveDateBeforeTermination
|
P180D | |
CY2021Q3 | adap |
Number Of Additional Terms
NumberOfAdditionalTerms
|
2 | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
108033000 | |
CY2022Q4 | us-gaap |
Marketable Securities
MarketableSecurities
|
96572000 | |
CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
1569000 | |
CY2022 | adap |
Concentration Risk Customers Number
ConcentrationRiskCustomersNumber
|
3 | |
CY2022Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
7435000 | |
CY2021Q4 | us-gaap |
Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
|
752000 | |
CY2022 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | |
CY2022Q4 | adap |
Receivables Past Due Amount
ReceivablesPastDueAmount
|
0 | |
CY2022Q4 | us-gaap |
Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
|
1.21 | |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
4170000 | |
CY2021Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y9M18D | |
CY2022Q4 | adap |
Tax Credit Receivable Current
TaxCreditReceivableCurrent
|
30162000 | |
CY2021Q4 | adap |
Tax Credit Receivable Current
TaxCreditReceivableCurrent
|
30773000 | |
CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
9472000 | |
CY2021Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
9043000 | |
CY2022Q4 | adap |
Clinical Materials Current
ClinicalMaterialsCurrent
|
1279000 | |
CY2021Q4 | adap |
Clinical Materials Current
ClinicalMaterialsCurrent
|
746000 | |
CY2022Q4 | us-gaap |
Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
|
490000 | |
CY2021Q4 | us-gaap |
Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
|
2482000 | |
CY2022Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
1927000 | |
CY2021Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
2082000 | |
CY2022Q4 | adap |
Prepaid Expense And Other Assets Current Including Acounts Receivable
PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable
|
43330000 | |
CY2021Q4 | adap |
Prepaid Expense And Other Assets Current Including Acounts Receivable
PrepaidExpenseAndOtherAssetsCurrentIncludingAcountsReceivable
|
45126000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
92104000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
66747000 | |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
38588000 | |
CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
36253000 | |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
53516000 | |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
30494000 | |
CY2022 | us-gaap |
Depreciation
Depreciation
|
5266000 | |
CY2021 | us-gaap |
Depreciation
Depreciation
|
5630000 | |
CY2020 | us-gaap |
Depreciation
Depreciation
|
6627000 | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.068 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
5118000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
5051000 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
4676000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
4051000 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
442000 | |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
1000000 | |
CY2022 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
809000 | |
CY2021 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
937000 | |
CY2020 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
967000 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
309000 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
105000 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
43000 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
1000 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
1000 | |
CY2022 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
4367000 | |
CY2021 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
4259000 | |
CY2022 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
389000 | |
CY2021 | us-gaap |
Short Term Lease Cost
ShortTermLeaseCost
|
419000 | |
CY2022 | us-gaap |
Lease Cost
LeaseCost
|
4756000 | |
CY2021 | us-gaap |
Lease Cost
LeaseCost
|
4678000 | |
CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
3746000 | |
CY2021 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
4101000 | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y10M24D | |
CY2021Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.068 | |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3953000 | |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
4001000 | |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
4055000 | |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
5471000 | |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
7324000 | |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
28974000 | |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
5897000 | |
CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
23077000 | |
CY2022Q1 | adap |
Amount Of Increase Decrease In Obligation And Right Of Use Asset For Operating Lease Following Lease Modification
AmountOfIncreaseDecreaseInObligationAndRightOfUseAssetForOperatingLeaseFollowingLeaseModification
|
75000 | |
CY2022Q4 | adap |
Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
|
16749000 | |
CY2021Q4 | adap |
Accrued Liabilities For Purchases Current
AccruedLiabilitiesForPurchasesCurrent
|
13436000 | |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
8232000 | |
CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11758000 | |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4079000 | |
CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4388000 | |
CY2022Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
2155000 | |
CY2021Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
327000 | |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
31215000 | |
CY2021Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
29909000 | |
CY2022Q4 | adap |
Stockholders Equity Note Show Of Hands Votes Per Share
StockholdersEquityNoteShowOfHandsVotesPerShare
|
1 | |
CY2022Q4 | adap |
Stockholders Equity Note Show Of Hands Votes Per Share
StockholdersEquityNoteShowOfHandsVotesPerShare
|
1 | |
CY2022Q4 | adap |
Stockholders Equity Note Show Of Hands Votes Per Share
StockholdersEquityNoteShowOfHandsVotesPerShare
|
1 | |
CY2022Q4 | adap |
Stockholders Equity Note Show Of Hands Votes Per Share
StockholdersEquityNoteShowOfHandsVotesPerShare
|
1 | |
CY2022Q4 | adap |
Stockholders Equity Note Poll Votes Per Share
StockholdersEquityNotePollVotesPerShare
|
1 | |
CY2021Q2 | adap |
Stockholders Equity Note Authority Of Directors To Allot New Shares Or Grant Rights Maximum Aggregate Nominal Amount
StockholdersEquityNoteAuthorityOfDirectorsToAllotNewSharesOrGrantRightsMaximumAggregateNominalAmount
|
310638.00 | |
CY2021Q2 | adap |
Stockholders Equity Note Authority Of Directors To Allot Shares Or Grant Rights Without First Offering To Existing Shareholders Maximum Aggregate Nominal Amount
StockholdersEquityNoteAuthorityOfDirectorsToAllotSharesOrGrantRightsWithoutFirstOfferingToExistingShareholdersMaximumAggregateNominalAmount
|
310638.00 | |
CY2015Q1 | adap |
Share Based Compensation Arrangement By Share Based Payment Award Options Schemes Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSchemesNumber
|
3 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
|
P10Y | |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
18240000 | |
CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
20629000 | |
CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
10414000 | |
CY2022Q4 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
14899000 | |
CY2022 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y7M6D | |
CY2022 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
5823534 | |
CY2021 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
5723646 | |
CY2020 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
11401390 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
2368000 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
4321000 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
8195000 | |
CY2022 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
50000 | |
CY2021 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
759000 | |
CY2020 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
5663000 | |
CY2022 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
|
488000 | |
CY2021 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
|
862000 | |
CY2020 | us-gaap |
Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options
EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
|
1265000 | |
CY2022Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
152539089 | |
CY2022 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P7Y | |
CY2022Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
0.44 | |
CY2022Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
75064373 | |
CY2022Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
0.64 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
CY2021 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P5Y | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2021 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2020 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-162959000 | |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-157299000 | |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-129930000 | |
CY2022 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
2492000 | |
CY2021 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
791000 | |
CY2020 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
162000 | |
CY2022 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
5000 | |
CY2022 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
2497000 | |
CY2021 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
791000 | |
CY2020 | us-gaap |
Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
|
162000 | |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
2497000 | |
CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
791000 | |
CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
162000 | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
3486000 | |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
922000 | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
|
1529000 | |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
|
1757000 | |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
|
251000 | |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
|
238000 | |
CY2022Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
5266000 | |
CY2021Q4 | us-gaap |
Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
|
2917000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
16963000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
|
15584000 | |
CY2022Q4 | adap |
Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
|
1324000 | |
CY2021Q4 | adap |
Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
|
2401000 | |
CY2022Q4 | adap |
Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
|
1958000 | |
CY2021Q4 | adap |
Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
|
2143000 | |
CY2022Q4 | adap |
Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
|
136592000 | |
CY2021Q4 | adap |
Deferred Tax Assets Operating Loss Carryforwards And Tax Credit Carryforwards
DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
|
114972000 | |
CY2022Q4 | adap |
Deferred Tax Asset Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetDeferredExpenseCapitalizedResearchAndDevelopmentCosts
|
8409000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
|
532000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
|
260000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
165778000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
135360000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
160512000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
132443000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
5266000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
2917000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
132443000 | |
CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
82398000 | |
CY2022 | adap |
Valuation Allowance Deferred Tax Asset Foreign Currency Translation Adjustments
ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslationAdjustments
|
-12222000 | |
CY2021 | adap |
Valuation Allowance Deferred Tax Asset Foreign Currency Translation Adjustments
ValuationAllowanceDeferredTaxAssetForeignCurrencyTranslationAdjustments
|
-1513000 | |
CY2022 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
28069000 | |
CY2021 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
50045000 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
160512000 | |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
132443000 | |
CY2021 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
21481000 | |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
CY2022Q4 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
71535000 | |
CY2021Q4 | us-gaap |
Noncurrent Assets
NoncurrentAssets
|
51369000 | |
CY2022Q4 | us-gaap |
Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
|
2285000 | |
CY2022Q4 | us-gaap |
Restructuring And Related Cost Expected Cost Remaining1
RestructuringAndRelatedCostExpectedCostRemaining1
|
947000 | |
CY2022Q4 | us-gaap |
Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
|
3232000 |